Want to see SABS full AI Analyst Report?
SAB Biotherapeutics (SABS) Ratios
SAB Biotherapeutics Ratios
SABS's free cash flow for Q2 2026 was $-26.68M. For the 2026 fiscal year, SABS's free cash flow was decreased by $-2.57M and operating cash flow was $-24.11M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.46 | 2.98 | 5.45 | 1.47 | 1.90 |
| Quick Ratio | 9.46 | 2.98 | 5.45 | 1.47 | 1.90 |
| Cash Ratio | 0.98 | 1.12 | 5.23 | 1.00 | 1.26 |
| Solvency Ratio | 0.77 | -1.61 | -1.44 | -0.78 | -0.36 |
| Operating Cash Flow Ratio | -4.19 | -4.30 | -2.32 | -1.56 | 0.08 |
| Short-Term Operating Cash Flow Coverage | -47.06 | -42.24 | -23.90 | -30.36 | 1.11 |
| Net Current Asset Value | $ 79.74M | $ 5.57M | $ 32.27M | $ 2.25M | $ 7.60M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.11 | 0.07 | 0.12 | 0.10 |
| Debt-to-Equity Ratio | 0.04 | 0.18 | 0.10 | 0.19 | 0.22 |
| Debt-to-Capital Ratio | 0.04 | 0.15 | 0.09 | 0.16 | 0.18 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| Financial Leverage Ratio | 1.14 | 1.70 | 1.46 | 1.64 | 2.10 |
| Debt Service Coverage Ratio | 13.92 | -25.65 | -27.91 | -14.10 | -7.27 |
| Interest Coverage Ratio | -203.41 | -134.77 | -120.76 | -95.89 | -45.48 |
| Debt to Market Cap | 0.01 | 0.02 | 0.03 | 0.05 | 0.01 |
| Interest Debt Per Share | 0.32 | 0.54 | 1.13 | 1.43 | 2.03 |
| Net Debt to EBITDA | -0.27 | 0.15 | 1.33 | 0.60 | 1.62 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | -262.41% | -67.26% | 86.23% | 97.28% |
| EBIT Margin | 0.00% | -2554.95% | -1870.43% | -77.03% | -27.68% |
| EBITDA Margin | 0.00% | -2192.54% | -1703.13% | -63.26% | -24.96% |
| Operating Profit Margin | 0.00% | -3244.87% | -1700.54% | -120.98% | -22.00% |
| Pretax Profit Margin | 0.00% | -2579.03% | -1884.50% | -78.29% | -28.16% |
| Net Profit Margin | 0.00% | -2579.03% | -1884.50% | -78.40% | -28.16% |
| Continuous Operations Profit Margin | 0.00% | -2579.03% | -1884.50% | -78.40% | -28.16% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.14% | 100.00% |
| EBT Per EBIT | -27.11% | 79.48% | 110.82% | 64.72% | 128.01% |
| Return on Assets (ROA) | 7.68% | -77.17% | -50.27% | -36.82% | -21.13% |
| Return on Equity (ROE) | 8.76% | -131.33% | -73.64% | -60.34% | -44.47% |
| Return on Capital Employed (ROCE) | -30.19% | -118.49% | -52.07% | -80.53% | -24.49% |
| Return on Invested Capital (ROIC) | -30.02% | -114.23% | -50.78% | -77.51% | -23.18% |
| Return on Tangible Assets | 7.68% | -77.17% | -50.27% | -36.82% | -21.13% |
| Earnings Yield | 18.38% | -97.16% | -111.08% | -73.00% | -5.05% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 24.06 | 0.00 | 4.30 | 7.60 |
| Payables Turnover | 0.98 | 2.83 | 3.96 | 0.89 | 0.37 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.07 | 0.09 | 0.84 | 1.97 |
| Asset Turnover | 0.00 | 0.03 | 0.03 | 0.47 | 0.75 |
| Working Capital Turnover Ratio | 0.00 | 0.04 | 0.08 | 1.55 | 2.58 |
| Cash Conversion Cycle | -372.61 | -113.90 | -92.19 | -323.08 | -935.86 |
| Days of Sales Outstanding | 0.00 | 15.17 | 0.00 | 84.85 | 48.03 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 372.61 | 129.07 | 92.19 | 407.92 | 983.89 |
| Operating Cycle | 0.00 | 15.17 | 0.00 | 84.85 | 48.03 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.32 | -3.70 | -4.55 | -5.39 | 0.46 |
| Free Cash Flow Per Share | -2.37 | -3.74 | -4.59 | -5.89 | -2.06 |
| Dividend Paid and CapEx Coverage Ratio | -47.98 | -101.68 | -127.41 | -10.83 | 0.18 |
| Capital Expenditure Coverage Ratio | -47.98 | -101.68 | -127.41 | -10.83 | 0.18 |
| Operating Cash Flow Coverage Ratio | -7.52 | -7.34 | -4.25 | -3.96 | 0.23 |
| Operating Cash Flow to Sales Ratio | 0.00 | -25.93 | -11.22 | -0.98 | 0.03 |
| Free Cash Flow Yield | -63.29% | -98.65% | -66.65% | -99.82% | -2.64% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 17.00 | -1.03 | -0.90 | -1.37 | -19.80 |
| Price-to-Sales (P/S) Ratio | 0.00 | 26.54 | 16.96 | 1.07 | 5.58 |
| Price-to-Book (P/B) Ratio | 0.48 | 1.35 | 0.66 | 0.83 | 8.81 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.58 | -1.01 | -1.50 | -1.00 | -37.90 |
| Price-to-Operating Cash Flow Ratio | -1.61 | -1.02 | -1.51 | -1.09 | 170.87 |
| Price-to-Earnings Growth (PEG) Ratio | -0.16 | 0.02 | -0.01 | -0.15 | 0.11 |
| Enterprise Value Multiple | 4.08 | -1.06 | 0.33 | -1.09 | -20.72 |
| Enterprise Value | 67.67M | 30.87M | -12.67M | 16.55M | 314.81M |
| EV to EBITDA | 4.08 | -1.06 | 0.33 | -1.09 | -20.72 |
| EV to Sales | 0.00 | 23.35 | -5.66 | 0.69 | 5.17 |
| EV to Free Cash Flow | -1.48 | -0.89 | 0.50 | -0.65 | -35.15 |
| EV to Operating Cash Flow | -1.51 | -0.90 | 0.50 | -0.71 | 158.44 |
| Tangible Book Value Per Share | 7.84 | 2.80 | 10.38 | 7.14 | 8.87 |
| Shareholders’ Equity Per Share | 7.84 | 2.80 | 10.38 | 7.14 | 8.87 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.14 | 0.41 | 5.49 | 14.00 |
| Net Income Per Share | 0.69 | -3.68 | -7.64 | -4.31 | -3.94 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.98 | 1.01 | 1.01 | 1.02 | 1.02 |
| Research & Development to Revenue | 0.00 | 22.81 | 7.38 | 1.52 | 0.94 |
| SG&A to Revenue | 0.00 | 7.01 | 10.63 | 0.69 | 0.28 |
| Stock-Based Compensation to Revenue | 0.00 | 2.22 | 1.08 | 0.11 | 0.04 |
| Income Quality | -3.37 | 1.01 | 0.60 | 1.25 | -0.12 |
Currency in USD
